Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Aachen

OncologyPhase II

What changed

Phase II trial registered: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

6w agoTrial registeredJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

74no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Nov 18, 2025
Cholangiocarcinoma, IDH Mutation · RECRUITING · sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
ClinicalTrials.gov · NCT07260175 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 1, 2019
Intrahepatic Cholangiocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
ClinicalTrials.gov · NCT04238637 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.96{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
new_entity links the trial record at 0.53{"reasons":["name similarity 100%","same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
6w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
7mo agoTrial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE2 registered

PHASE2 registered